Theravance Biopharma
TBPH
98 hedge funds and large institutions have $770M invested in Theravance Biopharma in 2016 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 46 increasing their positions, 18 reducing their positions, and 5 closing their positions.
360% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 5
156% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 18
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
45% more capital invested
Capital invested by funds: $529M → $770M (+$241M)
21% more funds holding
Funds holding: 81 → 98 (+17)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $79K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$41.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$29.3M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$24.2M |
| 4 |
BG
Baupost Group
Boston,
Massachusetts
|
+$18.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
-$9.73M |
| 2 |
AC
Armistice Capital
New York
|
-$7.52M |
| 3 |
D.E. Shaw & Co
New York
|
-$4.99M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$3.52M |
| 5 |
RA
Royce & Associates
New York
|
-$2.09M |
TBPH Hedge Fund Activity: Q2 2016 in Review
98 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q2 2016, worth a combined $770M — up 45% from $529M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new TBPH positions and 5 closed out — a net gain of 18 holders — while 46 added to existing stakes and 18 trimmed.
The largest buyer was Woodford Investment Management, adding an estimated $41.2M. The largest seller was OppenheimerFunds, cutting an estimated $9.73M.
- 98 institutional investors held Theravance Biopharma (TBPH) as of Q2 2016, up from 81 in Q1 2016.
- Funds reported $770M of Theravance Biopharma stock for Q2 2016, up 45% quarter-over-quarter.
- 23 funds opened new Theravance Biopharma positions in Q2 2016 and 5 closed out, a net change of +18 holders.
- The largest Theravance Biopharma buyer in Q2 2016 was Woodford Investment Management, an estimated $41.2M added.
- The largest Theravance Biopharma seller in Q2 2016 was OppenheimerFunds, an estimated $9.73M sold.
Based on aggregated 13F filings for Q2 2016.